Minnelide is under clinical development by Minneamrita Therapeutics and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The Pancreas have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Minnelide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Minnelide overview
Minnelide is under development for the treatment of gastrointestinal tumor, breast cancer, metastatic adenocarcinoma of the pancreas, hepatocellular carcinoma, malignant mesothelioma, non-small cell lung carcinoma, relapsed and refractory acute myeloid leukemia, gastric cancer and EGFR mutated non-small cell lung cancer. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). It was also under development for the treatment of epithelial ovarian cancer, neuroblastoma and osteosarcoma.
For a complete picture of Minnelide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.